TY - JOUR
T1 - A preliminary biodistribution study of [99mTc]sodium pertechnetate prepared from an electron linear accelerator and activated carbon-based 99mTc generator
AU - Jang, Jaewoong
AU - Kumakura, Yoshitaka
AU - Tatenuma, Katsuyoshi
AU - Ozeki, Atsuko Nakanishi
AU - Wada, Youichiro
AU - Akimitsu, Nobuyoshi
AU - Tsuguchi, Akira
AU - Kikunaga, Hidetoshi
AU - Higaki, Shogo
AU - Uesaka, Mitsuru
N1 - Funding Information:
This work was supported by the joint research programs of Isotope Science Center, the University of Tokyo (No. 19-10), and ELPH, Tohoku University (No. 2921). This paper contains part of a dissertation submitted by JJ to the University of Tokyo [29] , and part of a study conducted within the Coordinated Research Project on “New Ways of Producing Tc-99m and Tc-99m Generators (F22068)”, implemented by the International Atomic Energy Agency. Experimental assistance from M. Shiizu, N. Kosaka, K. Tao, and M. Ozeki (University of Tokyo) are appreciated.
Funding Information:
This work was supported by the joint research programs of Isotope Science Center, the University of Tokyo (No. 19-10), and ELPH, Tohoku University (No. 2921). This paper contains part of a dissertation submitted by JJ to the University of Tokyo [29], and part of a study conducted within the Coordinated Research Project on ?New Ways of Producing Tc-99m and Tc-99m Generators (F22068)?, implemented by the International Atomic Energy Agency. Experimental assistance from M. Shiizu, N. Kosaka, K. Tao, and M. Ozeki (University of Tokyo) are appreciated.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Introduction: Production of 99Mo/99mTc using an electron linear accelerator (linac) and activated carbon (AC)-based 99mTc generator (linac-AC) is an alternative approach to the conventional fission production of 99Mo/99mTc. As a preliminary investigation of the clinical applicability of a linac-AC-derived 99mTc radiopharmaceutical, the biodistribution of linac-AC-derived [99mTc]sodium pertechnetate ([99mTc]NaTcO4) was measured and compared against fission-derived [99mTc]NaTcO4 at one time point. Methods: 99Mo was produced by irradiating nonenriched MoO3 targets with bremsstrahlung photons generated from 55.5-MeV linac electron beams. 99mTc was then separated and purified from the 99Mo using an AC-based 99mTc generator. Subsequently, biodistribution of the linac-AC-derived [99mTc]NaTcO4 in healthy female Slc:ICR mice (n = 6) was measured by dissection and compared with that of fission-derived [99mTc]NaTcO4 (n = 4) at 30 min after injection. Results: The two types of [99mTc]NaTcO4 exhibited similar biodistribution in all the organs and tissues examined: the uptakes of [99mTc]NaTcO4 prepared from the linac-AC method and those prepared from the fission method were 138.9 ± 69.9%ID/g and 160.6 ± 49.2%ID/g in the thyroids, respectively, 33.4 ± 5.5%ID/g and 29.4 ± 9.1%ID/g in the salivary glands, respectively, and less than 10%ID/g in blood and all the other organs. No adverse effects were observed in the mice administered with either [99mTc]NaTcO4. Conclusion: The clinical applicability of linac-AC-derived [99mTc]NaTcO4 was suggested by its similar biodistribution with fission-derived [99mTc]NaTcO4 at one time point. Further biodistribution studies at multiple time points are encouraged to demonstrate the bioequivalence between linac-AC- and fission-derived [99mTc]NaTcO4.
AB - Introduction: Production of 99Mo/99mTc using an electron linear accelerator (linac) and activated carbon (AC)-based 99mTc generator (linac-AC) is an alternative approach to the conventional fission production of 99Mo/99mTc. As a preliminary investigation of the clinical applicability of a linac-AC-derived 99mTc radiopharmaceutical, the biodistribution of linac-AC-derived [99mTc]sodium pertechnetate ([99mTc]NaTcO4) was measured and compared against fission-derived [99mTc]NaTcO4 at one time point. Methods: 99Mo was produced by irradiating nonenriched MoO3 targets with bremsstrahlung photons generated from 55.5-MeV linac electron beams. 99mTc was then separated and purified from the 99Mo using an AC-based 99mTc generator. Subsequently, biodistribution of the linac-AC-derived [99mTc]NaTcO4 in healthy female Slc:ICR mice (n = 6) was measured by dissection and compared with that of fission-derived [99mTc]NaTcO4 (n = 4) at 30 min after injection. Results: The two types of [99mTc]NaTcO4 exhibited similar biodistribution in all the organs and tissues examined: the uptakes of [99mTc]NaTcO4 prepared from the linac-AC method and those prepared from the fission method were 138.9 ± 69.9%ID/g and 160.6 ± 49.2%ID/g in the thyroids, respectively, 33.4 ± 5.5%ID/g and 29.4 ± 9.1%ID/g in the salivary glands, respectively, and less than 10%ID/g in blood and all the other organs. No adverse effects were observed in the mice administered with either [99mTc]NaTcO4. Conclusion: The clinical applicability of linac-AC-derived [99mTc]NaTcO4 was suggested by its similar biodistribution with fission-derived [99mTc]NaTcO4 at one time point. Further biodistribution studies at multiple time points are encouraged to demonstrate the bioequivalence between linac-AC- and fission-derived [99mTc]NaTcO4.
KW - Activated carbon
KW - Biodistribution
KW - Electron linear accelerator
KW - Mo
KW - Pertechnetate
KW - Tc
UR - http://www.scopus.com/inward/record.url?scp=85128204062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128204062&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2022.03.002
DO - 10.1016/j.nucmedbio.2022.03.002
M3 - Article
C2 - 35429894
AN - SCOPUS:85128204062
SN - 0969-8051
VL - 110-111
SP - 1
EP - 9
JO - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
JF - International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
ER -
